SCHEMBL22228459

SCHEMBL22228459

CCCC1(CCC)c2cc(N)ccc2-c2ccc(N)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
LTK P29376 1/20 0.40
PRKX P51817 1/20 0.40
NEK2 P51955 1/20 0.40
JAK3 P52333 1/20 0.40
BTK Q06187 1/20 0.40
MAP4K2 Q12851 1/20 0.40
DYRK1A Q13627 1/20 0.40
TAOK1 Q7L7X3 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
PDK2 Q15119 2/20 0.39
ALDH1A1 P00352 5/20 0.34
MAPT P10636 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12095465 0.91 PDK2 (0.47) CHEK1PRKD3MAP4K4RETMET
SCHEMBL22228373 0.89 CHEK1 (0.41) CHEK1PRKD3MAP4K4RETMET
SCHEMBL2893208 0.85 CHEK1 (0.40) CHEK1PRKD3MAP4K4RETMET
SCHEMBL30569604 0.85 CHEK1 (0.40) CHEK1PRKD3MAP4K4RETMET
SCHEMBL30543304 0.85 CHEK1 (0.40) CHEK1PRKD3MAP4K4RETMET
SCHEMBL2776896 0.85 CHEK1 (0.40) CHEK1PRKD3MAP4K4RETMET
SCHEMBL30569606 0.85 CHEK1 (0.40) CHEK1PRKD3MAP4K4RETMET
SCHEMBL30656642 0.81 PDK2 (0.45) CHEK1PRKD3MAP4K4RETMET
SCHEMBL12095513 0.81 PDK2 (0.45) CHEK1PRKD3MAP4K4RETMET
SCHEMBL22294666 0.80 PDK2 (0.44) CHEK1PRKD3MAP4K4RETMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3686185-B1 FLUORENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING HCV-RELATED DISEASE SEOUL NAT UNIV R&DB FOUNDATION (KR) 2023-12-13 EP disclosed
US-11261175-B2 Fluorene derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for preventing or treating HCV-related disease SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2022-03-01 US disclosed
EP-3686185-A1 FLUORENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING HCV-RELATED DISEASE Seoul National University R & DB Foundation (KR) 2020-07-29 EP disclosed
US-20200231573-A1 Fluorene Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor, and Pharmaceutical Composition Comprising Same as Effective Ingredient for Preventing or Treating HCV-Related Disease POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11261175-B2 Fluorene derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for preventing or treating HCV-related disease SLC10A1, SLC39A11, FAR1 CHEK1 4804/4885PRKD3 4354/4885MAP4K4 4459/4885
US-20200231573-A1 Fluorene Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor, and Pharmaceutical Composition Comprising Same as Effective Ingredient for Preventing or Treating HCV-Related Disease SLC10A1, SLC39A11, FAR1 CHEK1 4804/4885PRKD3 4354/4885MAP4K4 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.